Correspondence

Somapacitan, lonapegsomatropin and somatrogon: ACMD advice

Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about 3 growth hormone agonists.

• From: Advisory Council on the Misuse of Drugs
• Published: 13 August 2025
• Last updated: 23 February 2026
  Show all updates

  1. 23 February 2026

     Added link to government response.

  2. 13 August 2025

     First published.

Documents

ACMD advice on somapacitan, lonapegsomatropin and somatrogon (accessible)

HTML

ACMD advice on somapacitan, lonapegsomatropin and somatrogon

PDF, 141 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Somapacitan, lonapegsomatropin and somatrogon have been granted a marketing authorisation in the UK. This letter provides advice on their classification and scheduling.

Read the government response to the 3 ACMD reports on medicines.